tbuckley/cabot-search huggingface dataset:
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial
Authors: Rosa I. Gallagher, Julia Wulfkuhle, Denise M. Wolf, Lamorna Brown-Swigart, Christina Yau, Nicholas O’Grady, Amrita Basu, Ruixiao Lu, Michael J. Campbell, Mark J. Magbanua, Jean-Philippe Coppé, Smita M. Asare, Laura Sit, Jeffrey B. Matthews, Jane Perlmutter, Nola Hylton, Minetta C. Liu, W. Fraser Symmans, Hope S. Rugo, Claudine Isaacs, Angela M. DeMichele, Douglas Yee, Paula R. Pohlmann, Gillian L. Hirst, Laura J. Esserman, Laura J. van ‘t Veer, Emanuel F. Petricoin
Journal: Cell Reports Medicine (2023)

Molecular subtyping of breast cancer is based mostly on HR/HER2 and gene expression-based immune, DNA repair deficiency, and luminal signatures. We extend this description via functional protein pathway activation mapping using pre-treatment, quantitative expression data from 139 proteins/phosphoproteins from 736 patients across 8 treatment arms of the I-SPY 2 Trial (ClinicalTrials.gov: NCT01042379). We identify predictive fit-for-purpose, mechanism-of-action-based signatures and individual predictive protein biomarker candidates by evaluating associations with pathologic complete response. Elevated levels of cyclin D1, estrogen receptor alpha, and androgen receptor S650 associate with non-response and are biomarkers for global resistance. We uncover protein/phosphoprotein-based signatures that can be utilized both for molecularly rationalized therapeutic selection and for response prediction. We introduce a dichotomous HER2 activation response predictive signature for stratifying triple-negative breast cancer patients to either HER2 or immune checkpoint therapy response as a model for how protein activation signatures provide a different lens to view the molecular landscape of breast cancer and synergize with transcriptomic-defined signatures.
Cortical somatostatin long-range projection neurons and interneurons exhibit divergent developmental trajectories
Authors: Josephine Fisher, Marieke Verhagen, Zhen Long, Monika Moissidis, Yiming Yan, Chenyi He, Jingyu Wang, Elia Micoli, Clara Milían Alastruey, Rani Moors, Oscar Marín, Da Mi, Lynette Lim
Journal: Neuron (2023)

The mammalian cerebral cortex contains an extraordinary diversity of cell types that emerge by implementing different developmental programs. Delineating when and how cellular diversification occurs is particularly challenging for cortical inhibitory neurons because they represent a small proportion of all cortical cells and have a protracted development. Here, we combine single-cell RNA sequencing and spatial transcriptomics to characterize the emergence of neuronal diversity among somatostatin-expressing (SST+) cells in mice. We found that SST+ inhibitory neurons segregate during embryonic stages into long-range projection (LRP) neurons and two types of interneurons, Martinotti cells and non-Martinotti cells, following distinct developmental trajectories. Two main subtypes of LRP neurons and several subtypes of interneurons are readily distinguishable in the embryo, although interneuron diversity is likely refined during early postnatal life. Our results suggest that the timing for cellular diversification is unique for different subtypes of SST+ neurons and particularly divergent for LRP neurons and interneurons.
Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study
Authors: Oihane Pérez-Escurza, Juan Flores-Montero, Jón Þórir Óskarsson, Luzalba Sanoja-Flores, Julio del Pozo, Quentin Lecrevisse, Silvia Martín, Elín Ruth Reed, Guðlaug Katrín Hákonardóttir, Stephen Harding, Sigrún Þorsteinsdóttir, Sæmundur Rögnvaldsson, Thorvardur Jon Love, Brian Durie, Sigurður Yngvi Kristinsson, Alberto Orfao
Journal: Blood Cancer Journal (2023)

Abstract Monoclonal gammopathy of undetermined significance (MGUS) is the earliest discernible stage of multiple myeloma (MM) and Waldenström’s macroglobulinemia (WM). Early diagnosis of MG may be compromised by the low-level infiltration, undetectable to low-sensitive methodologies. Here, we investigated the prevalence and immunophenotypic profile of clonal (c) plasma cells (PC) and/or cB-lymphocytes in bone marrow (BM) and blood of subjects with a serum M-component from the iSTOPMM program, using high-sensitive next-generation flow cytometry (NGF), and its utility in the diagnostic classification of early-stage MG. We studied 164 paired BM and blood samples from 82 subjects, focusing the analysis on: 55 MGUS, 12 smoldering MM (SMM) and 8 smoldering WM (SWM). cPC were detected in 84% of the BM samples and cB-lymphocytes in 45%, coexisting in 39% of cases. In 29% of patients, the phenotypic features of cPC and/or cB-lymphocytes allowed a more accurate disease classification, including: 19/55 (35%) MGUS, 1/12 (8%) SMM and 2/8 (25%) SWM. Blood samples were informative in 49% of the BM-positive cases. We demonstrated the utility of NGF for a more accurate diagnostic classification of early-stage MG.
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Authors: Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K. Buadi, Joselle Cook, David Dingli, Angela Dispenzieri, Amie L. Fonder, Morie A. Gertz, Wilson Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Rahma Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar
Journal: Blood Cancer Journal (2023)

Comparison of daratumumab
Association of Air Pollution with a Urinary Biomarker of Biological Aging and Effect Modification by Vitamin K in the FLEMENGHO Prospective Population Study
Authors: Dries S. Martens, De-Wei An, Yu-Ling Yu, Babangida S. Chori, Congrong Wang, Ana Inês Silva, Fang-Fei Wei, Chen Liu, Katarzyna Stolarz-Skrzypek, Marek Rajzer, Agnieszka Latosinska, Harald Mischak, Jan A. Staessen, Tim S. Nawrot
Journal: Environmental Health Perspectives (2023)

A recently developed urinary peptidomics biological aging clock can be used to study accelerated human aging. From 1990 to 2019, exposure to airborne particulate matter (PM) became the leading environmental risk factor worldwide.
Continuous measurement of quality is vital for improving care for women, newborns, and children in Nigeria
Authors: Ugo Okoli, Olumuyiwa Ojo, Kathleen Hill, Peter Baffoe, Anthony Adoghe
Journal: BMJ (2023)

<b>Ugo Okoli and colleagues</b> argue that much can be learnt from Nigeria’s efforts to strengthen continuous measurement of quality using routine data sources to help improve quality of care for women and children
Covid inquiry: What did Johnson say about underestimated risks, excess deaths, and his missing WhatsApps?
Authors: Gareth Iacobucci
Journal: BMJ (2023)

Whether it was his alleged reluctance to impose lockdowns, his oversight of a supposedly "toxic" atmosphere in Downing Street, or being bamboozled by science, 1 2 Boris Johnson has already been discussed at length during the UK's covid inquiry.This week the former UK prime minister had his say as he faced questions on 6 and 7 December.
Embedding implementation research to cross the quality of care chasm during the covid-19 pandemic and beyond
Authors: Michael A Peters, Keith Cloete, George Odwe, Gizachew Tadele, Lisa R Hirschhorn, Hema Magge, Sanam Roder-DeWan
Journal: BMJ (2023)

Quality of CareEmbedding implementation research to cross the quality of care chasm during the covid-19 pandemic and beyondMichael Peters and colleagues argue that concerted efforts to embed implementation research can improve health services, even in the most challenging operating environments • Donors, policymakers, implementers, and researchers all have critical part to play in prioritising embeddedness and strengthening the research and learning capacity of health systems on 11 December
Glucosylation endows nanoparticles with TLR4 agonist capability to trigger macrophage polarization and augment antitumor immunity
Authors: Li Liu, Shengxiang Fu, Wencheng Zhu, Zhongyuan Cai, Yingzi Cao, Yubing Huang, Li Yang, Xiaomin Fu, Rongrong Jin, Chunchao Xia, Yunjiao Zhang, Su Lui, Qiyong Gong, Bin Song, Longping Wen, James M. Anderson, Hua Ai
Journal: Biomaterials (2023)
Correction: Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU)
Authors: Carl Thomas Anthon, Frédéric Pène, Anders Perner, Elie Azoulay, Kathryn Puxty, Andry Van De Louw, Andreas Barratt-Due, Sanjay Chawla, Pedro Castro, Pedro Póvoa, Luis Coelho, Victoria Metaxa, Matthias Kochanek, Tobias Liebregts, Thomas Kander, Johanna Hästbacka, Jo Bønding Andreasen, Edwige Péju, Lene Bjerregaard Nielsen, Christine Lodberg Hvas, Etienne Dufranc, Emmanuel Canet, Linda Lundqvist, Christopher John Wright, Julien Schmidt, Fabrice Uhel, Hafid Ait-Oufella, Mette Krag, Elisabet Cos Badia, Cándido Díaz-Lagares, Sophie Menat, Guillaume Voiriot, Niels Erikstrup Clausen, Kristian Lorentzen, Reidar Kvåle, Thomas Hildebrandt, Aleksander Rygh Holten, Kristian Strand, Asterios Tzalavras, Morten Heiberg Bestle, Pål Klepstad, Sara Fernandez, Damien Vimpere, Carolina Paulino, Carina Graça, Catherina Lueck, Christian Svendsen Juhl, Carolina Costa, Per Martin Bådstøløkken, Teresa Miranda, Lia Susana Aires Lêdo, Joao Carlos Sousa Torres, Anders Granholm, Morten Hylander Møller, Lene Russell, Ahmed Khalil, Ahmed Yehia, Haney Salem, Hesham Farahat, Manu Sudevan, Melissa Biggart, Nirmeen Fatima, Mohammed Elkhonezy, Anne-Marie Bunzel, Rine M. Siegumfeldt, Stine R. Vestergaard, Juliette Pelle, Minh-Pierre Lê, Clara Vigneron, Morgane Bertrix, Paul Cirera, Driss Laghlam, Swann Bredin, Nathalie Marin, Maria Toppenberg, Brice Benelli, Amélie Seguin, Charlotte Garret, Florian Guillotin, Gauthier Blonz, Jean-Baptiste Lascarrou, Jérémie Lemarie, Luc Desmedt, Maïté Agbakou, Mathieu Carpentier, Maëlle Martin, Naïla Benkalfate, Olivier Zambon, Paul Decamps, Pauline L. Wilquin, Soraya Benguerfi, John Gardner, Natalie Remor, Sheila Carr, Gloria Yang, Coralie Gernez, Ingrid Thiry, Louai Missri, Moritz K. G. Denneborg, Katherine Brown, Vanessa Casares, Mirka Sivula, Elina Lappi, Leena Pettilä, Jonna Heinonen, Minttu Saario, Manal K. Mecheri, Alezandre Elabbadi, Cyrielle Desnos, Antoine Lafarge, Olfa Mghirbi, Brit Å. Sjøbø, Cecilie Christoffersen, Frederik H. Bestle, Claudia Lemos, Cristiana V. Gonçalves, Nuno M. B. Jacinto, Monica P. Anselmo, Marius M. Hoeper, Marja Hoff, Pedro M. Simões Freire
Journal: Intensive Care Medicine (2023)

was given in a misleading wording.Instead of "Absence of acquired immune deficiency syndrome (AIDS), non-cancer-related immune deficiency, liver failure, male sex, septic shock, and bleeding at ICU admission were associated with the development of thrombocytopenia during ICU stay".it should read "Non-AIDS-, non-cancer-related immune deficiency, liver failure, male sex, septic shock, and bleeding at ICU admission were associated with the development of thrombocytopenia during ICU stay.
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: <i>Standards of Care in Diabetes–2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Robert F. Kushner, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Index
Journal: Diabetes Care (2023)

disease and, S116-S117 by CGM, S112, S113-S114 confirming diagnosis with, S22 correlation with BGM, S112 diabetes distress and, S94 equivalent eAG levels, S112 for diabetes screening and diagnosis, S21-S22 glycemic assessment by, S7, S112 hemoglobinopathies and, S22 in children, S30, S263-S264, S268, S269, S270-S271 in cystic fibrosis-related disease, S31 in gestational diabetes mellitus, S34-S35 in hyperglycemia, S64 in people with HIV, S30 in preclinical type 1 diabetes
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Elizabeth A. Beverly, Dennis Bruemmer, Billy S. Collins, Audrey Darville, Laya Ekhlaspour, Mohamed Hassanein, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
11. Chronic Kidney Disease and Risk Management: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Kenneth Cusi, Laya Ekhlaspour, Talya K. Fleming, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Nicola Napoli, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Monica Verduzco-Gutierrez, Zobair M. Younossi, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
6. Glycemic Goals and Hypoglycemia: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Elizabeth Selvin, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
2. Diagnosis and Classification of Diabetes: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Jason L. Gaglia, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Elizabeth Selvin, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Introduction and Methodology: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Elizabeth A. Beverly, Dennis Bruemmer, Billy S. Collins, Kenneth Cusi, Audrey Darville, Sandeep R. Das, Laya Ekhlaspour, Talya K. Fleming, Jason L. Gaglia, Rodolfo J. Galindo, Christopher H. Gibbons, John M. Giurini, Mohamed Hassanein, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Mikhail N. Kosiborod, Robert F. Kushner, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Lisa Murdock, Nicola Napoli, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Elizabeth Selvin, Paolo S. Silva, Robert C. Stanton, Monica Verduzco-Gutierrez, Crystal C. Woodward, Zobair M. Younossi, Robert A. Gabbay
Journal: Diabetes Care (2023)
14. Children and Adolescents: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
13. Older Adults: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.